Gilead Sciences Q4 2025 HIV Sales Propel Revenue Growth, Margin Expansion
Gilead Sciences said Q4 2025 earnings call highlighted strong HIV therapy sales driving year-over-year revenue growth and supporting margin expansion. Executives emphasized sustained demand for Biktarvy and Apretude while outlining capital allocation plans for share repurchases and continued R&D investment.
1. HIV Sales Drive Q4 Revenue Growth
In the fourth quarter of 2025, Gilead’s HIV franchise posted robust sales gains, led by its flagship Biktarvy regimen and long-acting Apretude injection. The uplift in antiviral revenues underpinned overall top-line growth and offset headwinds in other therapeutic areas.
2. Margin Expansion and Profitability
Improved product mix and operational efficiencies contributed to expanded gross and operating margins in Q4, bolstering adjusted EPS results. Management cited cost controls in manufacturing and streamlined SG&A spending as key drivers of profit improvement.
3. Capital Allocation and R&D Focus
Gilead reiterated its commitment to returning capital through an enhanced share repurchase program and maintaining dividend payouts. The company also pledged sustained R&D investment in next-generation antivirals and oncology pipeline assets to fuel future growth.